Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient concerns about technology understanding and insurance coverage, as well as the reliance on traditional tissue biopsies, emphasizing the benefits of combining liquid and tissue biopsies to improve treatment outcomes and clinical trial eligibility.